The inhibitor demonstrates selective activity against MTAP-depleted cancers both in vitro and in vivo, effectively reducing sDMA levels in cancer cells while sparing normal tissues [22], thereby showcasing a favorable therapeutic window. The gene discussed is MTAP; the disease is cancer.